-SEC Filing
Aligos Therapeutics To Present Nonclinical And Clinical Data For Its Chronic Hepatitis B And NASH Portfolio At AASLD’s The Liver Meeting 2022 November 4-8
Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced seven upcoming